Ministry of Chemicals and Fertilizers : press release · 13 April 2026 · pibtracker filter

India Pharma 2026 Showcases Sectoral Transformation Through Four Key Plenary Discussions

PRID2251694 MinistryMinistry of Chemicals and Fertilizers : Released13 April 2026 Reading12 min

Spotlight on Policy, Regulation, AI and CRDMO at India Pharma 2026 Posted On: 13 APR 2026 8:34PM by PIB Delhi The first day of the 9th India Pharma 2026 witnessed four high-impact plenary sessions that brought together policymakers, industry leaders, regulators and technology experts to chart the future of India’s pharmaceutical and life sciences ecosystem. The discussions reflected a strong consensus on accelerating innovation through policy support, regulatory transformation and adoption of next-generation technologies. The inaugural plenary session on “Policy Thrust for Catalysing Innovation” , highlighted the urgent need to bridge the gap between policy intent and on-ground execution. Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasised industry-led model for Research and Development, importance of strengthening government lab networks and attuning regulatory model to that of European systems. Shri Rajiv Bahl, Secretary Department of Health Research said though research funding has increased manifold over the last few years, the country needs a Bharat model of R & D with confidence of the market in the innovators and increased trust between industry and academica. Industry leaders echoed the need for increased venture capital participation and co-funding mechanisms to nurture research-driven enterprises, stronger industry-academia integration and underscored the importance of integrated ecosystems to translate early-stage discoveries into global solutions. The session concluded with a strong call to “Discover in India” and position the country as a global innovation hub. The second plenary session on “Enabling Regulatory Ecosystem to Foster Innovation” focused on creating a predictable, efficient and globally aligned regulatory framework. Dr. Rajeev Singh Raghuvanshi, Drug Controller General of India highlighted the importance of stakeholder consultations in shaping responsive regulatory systems. Industry Experts called for expedited approval pathways, single-window clearance mechanisms and greater global harmonisation to reduce duplication and accelerate patient access. Industry leaders further underlined the need for digital enablement and continuous collaboration between regulators and industry. The session underscored that a future-ready regulatory ecosystem will be critical to unlocking next-generation therapies and strengthening India’s global competitiveness. The third plenary session on “Harnessing AI and Next-Gen Technologies for Disruptive Innovation” explored the transformative potential of artificial intelligence across the pharmaceutical value chain. Pharma leaders emphasised reimagining processes rather than merely digitising existing systems. They highlighted the growing importance of strong data and technology foundations to enable scalable AI adoption and stressed the immediate benefits of automation in improving clinical efficiency. The session concluded on a forward-looking note, with experts agreeing that AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem. The fourth plenary session on “Unleashing India’s CRDMO Potential” brought focus to India’s growing role in the global Contract Research, Development and Manufacturing Organization (CRDMO) landscape. The panel noted that India’s CRDMO industry, currently valued at around $8 billion, has been growing at a robust pace of 10–12 percent, reflecting strong global outsourcing demand. Industry leaders stressed that speed will be a critical differentiator in scaling India’s R&D and manufacturing capabilities, and highlighted the transformative role of AI and digital technologies, including digital twins, in reshaping the CRDMO ecosystem. The session concluded by outlining the strategic priorities required for India to lead the next phase of global growth in complex modalities and outsourced pharma services. Overall, the plenary sessions on Day 1 of India Pharma 2026 reinforced India’s readiness to lead the next phase of global pharmaceutical innovation, driven by policy intent, regulatory agility and technological advancement. *** PC/PM (Release ID: 2251694) Visitor Counter : 895 Read this release in: Urdu , हिन्दी Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals India Pharma 2026 Showcases Sectoral Transformation Through Four Key Plenary Discussions  Spotlight on Policy, Regulation, AI and CRDMO at India Pharma 2026 Posted On: 13 APR 2026 8:34PM by PIB Delhi The first day of the 9th India Pharma 2026 witnessed four high-impact plenary sessions that brought together policymakers, industry leaders, regulators and technology experts to chart the future of India’s pharmaceutical and life sciences ecosystem. The discussions reflected a strong consensus on accelerating innovation through policy support, regulatory transformation and adoption of next-generation technologies. The inaugural plenary session on “Policy Thrust for Catalysing Innovation” , highlighted the urgent need to bridge the gap between policy intent and on-ground execution. Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasised industry-led model for Research and Development, importance of strengthening government lab networks and attuning regulatory model to that of European systems. Shri Rajiv Bahl, Secretary Department of Health Research said though research funding has increased manifold over the last few years, the country needs a Bharat model of R & D with confidence of the market in the innovators and increased trust between industry and academica. Industry leaders echoed the need for increased venture capital participation and co-funding mechanisms to nurture research-driven enterprises, stronger industry-academia integration and underscored the importance of integrated ecosystems to translate early-stage discoveries into global solutions. The session concluded with a strong call to “Discover in India” and position the country as a global innovation hub. The second plenary session on “Enabling Regulatory Ecosystem to Foster Innovation” focused on creating a predictable, efficient and globally aligned regulatory framework. Dr. Rajeev Singh Raghuvanshi, Drug Controller General of India highlighted the importance of stakeholder consultations in shaping responsive regulatory systems. Industry Experts called for expedited approval pathways, single-window clearance mechanisms and greater global harmonisation to reduce duplication and accelerate patient access. Industry leaders further underlined the need for digital enablement and continuous collaboration between regulators and industry. The session underscored that a future-ready regulatory ecosystem will be critical to unlocking next-generation therapies and strengthening India’s global competitiveness. The third plenary session on “Harnessing AI and Next-Gen Technologies for Disruptive Innovation” explored the transformative potential of artificial intelligence across the pharmaceutical value chain. Pharma leaders emphasised reimagining processes rather than merely digitising existing systems. They highlighted the growing importance of strong data and technology foundations to enable scalable AI adoption and stressed the immediate benefits of automation in improving clinical efficiency. The session concluded on a forward-looking note, with experts agreeing that AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem. The fourth plenary session on “Unleashing India’s CRDMO Potential” brought focus to India’s growing role in the global Contract Research, Development and Manufacturing Organization (CRDMO) landscape. The panel noted that India’s CRDMO industry, currently valued at around $8 billion, has been growing at a robust pace of 10–12 percent, reflecting strong global outsourcing demand. Industry leaders stressed that speed will be a critical differentiator in scaling India’s R&D and manufacturing capabilities, and highlighted the transformative role of AI and digital technologies, including digital twins, in reshaping the CRDMO ecosystem. The session concluded by outlining the strategic priorities required for India to lead the next phase of global growth in complex modalities and outsourced pharma services. Overall, the plenary sessions on Day 1 of India Pharma 2026 reinforced India’s readiness to lead the next phase of global pharmaceutical innovation, driven by policy intent, regulatory agility and technological advancement. *** PC/PM (Release ID: 2251694)  Spotlight on Policy, Regulation, AI and CRDMO at India Pharma 2026" /> The first day of the 9th India Pharma 2026 witnessed four high-impact plenary sessions that brought together policymakers, industry leaders, regulators and technology experts to chart the future of India’s pharmaceutical and life sciences ecosystem. The discussions reflected a strong consensus on accelerating innovation through policy support, regulatory transformation and adoption of next-generation technologies. <img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image0011I2W.jpg" style="height:373px; width:602px" /> The inaugural plenary session on “Policy Thrust for Catalysing Innovation”, highlighted the urgent need to bridge the gap between policy intent and on-ground execution. Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, emphasised industry-led model for Research and Development, importance of strengthening government lab networks and attuning regulatory model to that of European systems. Shri Rajiv Bahl, Secretary Department of Health Research said though research funding has increased manifold over the last few years, the country needs a Bharat model of R & D with confidence of the market in the innovators and increased trust between industry and academica. Industry leaders echoed the need for increased venture capital participation and co-funding mechanisms to nurture research-driven enterprises, stronger industry-academia integration and underscored the importance of integrated ecosystems to translate early-stage discoveries into global solutions. The session concluded with a strong call to “Discover in India” and position the country as a global innovation hub. <img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image002SK5U.jpg" style="height:401px; width:602px" /> The second plenary session on “Enabling Regulatory Ecosystem to Foster Innovation” focused on creating a predictable, efficient and globally aligned regulatory framework. Dr. Rajeev Singh Raghuvanshi, Drug Controller General of India highlighted the importance of stakeholder consultations in shaping responsive regulatory systems. Industry Experts called for expedited approval pathways, single-window clearance mechanisms and greater global harmonisation to reduce duplication and accelerate patient access. Industry leaders further underlined the need for digital enablement and continuous collaboration between regulators and industry. The session underscored that a future-ready regulatory ecosystem will be critical to unlocking next-generation therapies and strengthening India’s global competitiveness. <img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image0032KLJ.jpg" style="height:401px; width:602px" /> The third plenary session on “Harnessing AI and Next-Gen Technologies for Disruptive Innovation”  explored the transformative potential of artificial intelligence across the pharmaceutical value chain. Pharma leaders emphasised reimagining processes rather than merely digitising existing systems. They highlighted the growing importance of strong data and technology foundations to enable scalable AI adoption and  stressed the immediate benefits of automation in improving clinical efficiency. The session concluded on a forward-looking note, with experts agreeing that AI will play a pivotal role in accelerating drug discovery, enabling precision medicine and shaping a smarter, innovation-led healthcare ecosystem. <img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image0045I53.jpg" style="height:401px; width:602px" /> The fourth plenary session on “Unleashing India’s CRDMO Potential” brought focus to India’s growing role in the global Contract Research, Development and Manufacturing Organization (CRDMO) landscape. The panel noted that India’s CRDMO industry, currently valued at around $8 billion, has been growing at a robust pace of 10–12 percent, reflecting strong global outsourcing demand. Industry leaders stressed that speed will be a critical differentiator in scaling India’s R&D and manufacturing capabilities, and highlighted the transformative role of AI and digital technologies, including digital twins, in reshaping the CRDMO ecosystem. The session concluded by outlining the strategic priorities required for India to lead the next phase of global growth in complex modalities and outsourced pharma services. Overall, the plenary sessions on Day 1 of India Pharma 2026 reinforced India’s readiness to lead the next phase of global pharmaceutical innovation, driven by policy intent, regulatory agility and technological advancement. *** PC/PM " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //

Original PIB release
pib.gov.in · PRID 2251694

Open on PIB ↗

India Pharma 2026 Showcases Sectoral Transformation Through Four Key Plenary Discussions

More from this day